Your browser doesn't support javascript.
loading
Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density.
Stout, Natasha K; Miglioretti, Diana L; Su, Yu-Ru; Lee, Christoph I; Abraham, Linn; Alagoz, Oguzhan; de Koning, Harry J; Hampton, John M; Henderson, Louise; Lowry, Kathryn P; Mandelblatt, Jeanne S; Onega, Tracy; Schechter, Clyde B; Sprague, Brian L; Stein, Sarah; Trentham-Dietz, Amy; van Ravesteyn, Nicolien T; Wernli, Karen J; Kerlikowske, Karla; Tosteson, Anna N A.
Afiliação
  • Stout NK; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
  • Miglioretti DL; Department of Public Health Sciences, University of California Davis School of Medicine, Davis.
  • Su YR; Kaiser Permanente Washington Health Research Institute, Seattle.
  • Lee CI; Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle.
  • Abraham L; Kaiser Permanente Washington Health Research Institute, Seattle.
  • Alagoz O; Department of Industrial and Systems Engineering and Department of Population Health Sciences and Carbone Cancer Center, University of Wisconsin-Madison, Madison.
  • de Koning HJ; Department of Public Health, Erasmus University Medical Center Rotterdam, the Netherlands.
  • Hampton JM; Department of Industrial and Systems Engineering and Department of Population Health Sciences and Carbone Cancer Center, University of Wisconsin-Madison, Madison.
  • Henderson L; Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill.
  • Lowry KP; Fred Hutchinson Cancer Center University of Washington School of Medicine, Seattle.
  • Mandelblatt JS; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Department of Oncology and Georgetown Lombardi Institute for Cancer and Aging REsearch (I-CARE), Georgetown University, Washington, DC.
  • Onega T; Department of Population Health Sciences, and the Huntsman Cancer Institute, University of Utah, Salt Lake City.
  • Schechter CB; Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, New York.
  • Sprague BL; Department of Surgery, University of Vermont Cancer Center, Burlington, Vermont.
  • Stein S; University of Vermont Larner College of Medicine, Burlington.
  • Trentham-Dietz A; Department of Radiology, University of Vermont Cancer Center, Burlington, Vermont.
  • van Ravesteyn NT; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
  • Wernli KJ; Department of Population Health Sciences and Carbone Cancer Center, University of Wisconsin-Madison, Madison.
  • Kerlikowske K; Department of Public Health, Erasmus University Medical Center Rotterdam, the Netherlands.
  • Tosteson ANA; Kaiser Permanente Washington Health Research Institute, Seattle.
JAMA Intern Med ; 2024 Aug 26.
Article em En | MEDLINE | ID: mdl-39186304
ABSTRACT
Importance Information on long-term benefits and harms of screening with digital breast tomosynthesis (DBT) with or without supplemental breast magnetic resonance imaging (MRI) is needed for clinical and policy discussions, particularly for patients with dense breasts.

Objective:

To project long-term population-based outcomes for breast cancer mammography screening strategies (DBT or digital mammography) with or without supplemental MRI by breast density. Design, Setting, and

Participants:

Collaborative modeling using 3 Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer simulation models informed by US Breast Cancer Surveillance Consortium data. Simulated women born in 1980 with average breast cancer risk were included. Modeling analyses were conducted from January 2020 to December 2023. Intervention Annual or biennial mammography screening with or without supplemental MRI by breast density starting at ages 40, 45, or 50 years through age 74 years. Main outcomes and

Measures:

Lifetime breast cancer deaths averted, false-positive recall and false-positive biopsy recommendations per 1000 simulated women followed-up from age 40 years to death summarized as means and ranges across models.

Results:

Biennial DBT screening for all simulated women started at age 50 vs 40 years averted 7.4 vs 8.5 breast cancer deaths, respectively, and led to 884 vs 1392 false-positive recalls and 151 vs 221 false-positive biopsy recommendations, respectively. Biennial digital mammography had similar deaths averted and slightly more false-positive test results than DBT screening. Adding MRI for women with extremely dense breasts to biennial DBT screening for women aged 50 to 74 years increased deaths averted (7.6 vs 7.4), false-positive recalls (919 vs 884), and false-positive biopsy recommendations (180 vs 151). Extending supplemental MRI to women with heterogeneously or extremely dense breasts further increased deaths averted (8.0 vs 7.4), false-positive recalls (1088 vs 884), and false-positive biopsy recommendations (343 vs 151). The same strategy for women aged 40 to 74 years averted 9.5 deaths but led to 1850 false-positive recalls and 628 false-positive biopsy recommendations. Annual screening modestly increased estimated deaths averted but markedly increased estimated false-positive results. Conclusions and relevance In this model-based comparative effectiveness analysis, supplemental MRI for women with dense breasts added to DBT screening led to greater benefits and increased harms. The balance of this trade-off for supplemental MRI use was more favorable when MRI was targeted to women with extremely dense breasts who comprise approximately 10% of the population.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article